Novateor Research Laboratories Ltd
₹ 25.1
-3.46%
18 Nov
- close price
About
Incorporated in 2011, Novateor Research Laboratories Ltd is in the business of Oral Care and Personal Care products.[1]
Key Points
- Market Cap ₹ 15.2 Cr.
- Current Price ₹ 25.1
- High / Low ₹ 57.5 / 23.0
- Stock P/E 506
- Book Value ₹ 18.8
- Dividend Yield 0.00 %
- ROCE 1.69 %
- ROE 0.83 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -0.70%
- Company has a low return on equity of 0.58% over last 3 years.
- Company has high debtors of 272 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.03 | 0.02 | 0.10 | 0.14 | 0.09 | 0.41 | 0.39 | 0.19 | 0.74 | 1.26 | 1.21 | 2.78 | 4.45 | |
| 0.03 | 0.02 | 0.11 | 0.08 | 0.04 | 0.13 | 0.53 | 0.52 | 0.92 | 1.60 | 1.54 | 2.92 | 4.59 | |
| Operating Profit | 0.00 | 0.00 | -0.01 | 0.06 | 0.05 | 0.28 | -0.14 | -0.33 | -0.18 | -0.34 | -0.33 | -0.14 | -0.14 |
| OPM % | 0.00% | 0.00% | -10.00% | 42.86% | 55.56% | 68.29% | -35.90% | -173.68% | -24.32% | -26.98% | -27.27% | -5.04% | -3.15% |
| 0.00 | 0.00 | 0.01 | 0.02 | 0.03 | 0.11 | 0.27 | 0.44 | 0.01 | 0.49 | 0.49 | 0.48 | 0.49 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.02 | 0.03 | 0.07 | 0.10 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.07 | 0.07 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.08 | 0.16 | 0.19 |
| Profit before tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 0.02 | 0.01 | -0.26 | 0.04 | 0.05 | 0.11 | 0.06 |
| Tax % | 24.14% | 150.00% | 0.00% | -11.54% | 0.00% | 40.00% | 27.27% | ||||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | -0.01 | 0.01 | -0.23 | 0.04 | 0.03 | 0.08 | 0.03 | |
| EPS in Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.74 | -0.02 | 0.02 | -0.48 | 0.08 | 0.06 | 0.17 | 0.07 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 64% |
| 5 Years: | 48% |
| 3 Years: | 55% |
| TTM: | 171% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 58% |
| 3 Years: | -31% |
| TTM: | -57% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 46% |
| 3 Years: | 22% |
| 1 Year: | -47% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 2.96 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 6.05 |
| Reserves | 0.88 | 0.88 | 0.88 | 0.88 | 0.88 | 1.11 | 3.73 | 3.74 | 3.01 | 3.04 | 3.93 | 5.71 | 5.33 |
| 0.59 | 0.75 | 0.76 | 0.87 | 0.82 | 0.01 | 0.00 | 0.24 | 0.24 | 0.84 | 1.11 | 0.91 | 0.72 | |
| 0.00 | 0.11 | 0.15 | 0.10 | 0.09 | 0.24 | 0.23 | 0.17 | 0.06 | 0.24 | 0.59 | 1.16 | 1.76 | |
| Total Liabilities | 1.52 | 1.79 | 1.84 | 1.90 | 1.84 | 4.32 | 8.79 | 8.98 | 8.14 | 8.95 | 10.46 | 12.61 | 13.86 |
| 1.41 | 1.59 | 1.64 | 1.66 | 1.59 | 3.55 | 3.45 | 3.36 | 1.94 | 1.78 | 2.43 | 3.41 | 3.32 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.44 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| 0.10 | 0.19 | 0.19 | 0.23 | 0.24 | 0.76 | 5.33 | 5.61 | 6.19 | 6.73 | 7.58 | 9.19 | 10.53 | |
| Total Assets | 1.52 | 1.79 | 1.84 | 1.90 | 1.84 | 4.32 | 8.79 | 8.98 | 8.14 | 8.95 | 10.46 | 12.61 | 13.86 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.01 | 0.05 | -0.07 | -3.42 | -0.27 | -0.97 | -0.97 | -0.98 | -1.03 | |
| 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -1.96 | -0.10 | -0.09 | 0.91 | 0.13 | -0.25 | -0.22 | |
| 0.00 | 0.00 | 0.00 | 0.00 | -0.03 | 2.03 | 4.18 | 0.32 | -0.13 | 0.58 | 1.10 | 1.43 | |
| Net Cash Flow | 0.00 | 0.00 | 0.00 | -0.01 | 0.02 | 0.00 | 0.67 | -0.04 | -0.18 | -0.26 | -0.13 | 0.18 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365.00 | 365.00 | 219.00 | 182.50 | 243.33 | 133.54 | 233.97 | 384.21 | 212.09 | 202.78 | 337.85 | 271.78 |
| Inventory Days | 2,190.00 | 4,380.00 | 438.00 | 1,460.00 | 2,737.50 | 6,448.33 | 700.80 | 851.67 | 344.34 | 215.16 | 268.95 | 151.10 |
| Days Payable | 365.00 | 1,460.00 | 292.00 | 730.00 | 1,095.00 | 1,460.00 | 14.60 | 104.29 | 20.66 | 61.47 | 207.47 | 176.61 |
| Cash Conversion Cycle | 2,190.00 | 3,285.00 | 365.00 | 912.50 | 1,885.83 | 5,121.87 | 920.17 | 1,131.59 | 535.77 | 356.46 | 399.32 | 246.27 |
| Working Capital Days | 973.33 | 1,277.50 | 109.50 | 286.79 | 527.22 | 462.93 | 4,117.95 | 9,067.37 | 2,747.36 | 1,604.84 | 1,879.30 | 950.58 |
| ROCE % | 0.00% | 0.00% | 0.57% | 0.56% | 9.95% | 0.47% | 0.12% | 2.49% | 0.71% | 0.86% | 1.69% |
Documents
Announcements
-
Board Meeting Outcome for Unaudited Financial Results For The Half Year Ended On September 30 2025
14 Nov - Board approved H1 results to Sep 30, 2025: revenue Rs247.00 lakh; auditor qualified.
- Unaudited Financial Results For The Half Year Ended On 30.09.2025 14 Nov
-
Board Meeting Intimation for Adoption Of Financial Results For The Half Year Ended On September 30, 2025
8 Nov - Board meeting on Nov 14, 2025 to consider unaudited H1 results for period ended Sep 30, 2025; trading window closed.
-
Appointment of Company Secretary and Compliance Officer
3 Nov - Pooja Bafna Rathi appointed Company Secretary cum Compliance Officer and Whole-Time KMP effective 3 Nov 2025; nil shareholding.
-
Non Applicability Of Submission Of Related Party Disclosures For The Half Year Ended On September 30, 2025
6 Oct - Novateor: Related-party disclosures not applicable for half-year ended September 30, 2025 due to SME listing.
Business Overview:[1]
a) NRLL develops FDA-approved personal care products for clinical and commercial purposes.
b) It’s current Teeth Whitening products
are sold under the brand name Smile Shine
c) The company manufactures 3 different variants of Teeth Whitening Strips, Teeth White
Toothpaste and brush, Kids Toothpaste and
tongue cleaner, Teeth Whitening Gel, Power
Brush.
d) It intends to expand its business in cosmetics, various health care pharma products in the near future
e) The company’s customer base consists of Dentists as well as Cosmetic Parlors